EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase IV)Open Access · CC BY 4.0

Results of the Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-Controlled Study (SHARP)

Hans P A Van Dongen, Eileen B Leary, Christopher Drake, Richard Bogan, Judith Jaeger, Russell Rosenberg, Caroline Streicher, Herriot Tabuteau

CHEST · 2025

DOI: 10.1016/j.chest.2024.10.050 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift CHEST, 2025. Verfasst von Hans P A Van Dongen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine and Physiology & Sleep and Performance Research Center, Washington State University, Spokane, WA. Hauptthemen laut MEDLINE: Cognition, Sleep Apnea, Obstructive, Disorders of Excessive Somnolence, Cognitive Dysfunction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jazz Pharmaceuticals plc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: OSA causes episodes of fragmented sleep and intermittent hypoxia and leads to excessive daytime sleepiness (EDS). Deficits in cognitive function are a troublesome symptom in patients with OSA and EDS. RESEARCH QUESTION: How does solriamfetol affect cognitive function in patients with cognitive impairment associated with OSA and EDS? STUDY DESIGN AND METHODS: Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-Controlled Study (SHARP) was a phase IV, randomized double-blind placebo-controlled crossover trial. Participants (N = 59) were randomized to receive placebo or solriamfetol (75 mg/d for 3 days, then 150 mg/d) for 2 weeks, with crossover separated by a 1-week washout period. Efficacy measures included the Coding subtest, comparable to the Digit Symbol Substitution Test (DSST), of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the British Columbia Cognitive Complaints Inventory (BC-CCI), the Patient Global Impression of Severity (PGI-S), and the Epworth Sleepiness Scale (ESS). The primary end point was change from baseline in average postdose DSST RBANS scores. Secondary end points were changes from baseline in BC-CCI, PGI-S, ESS, and DSST RBANS scores at 2, 4, 6, and 8 hours' postdose. Safety was monitored by assessment of treatment-emergent adverse events. RESULTS: Solriamfetol was shown to significantly improve postdose average DSST RBANS scores compared with placebo (P = .009; effect size [Cohen's d], 0.37). When evaluated at each 2-hour time point, cognitive function was significantly improved at 2, 6, and 8 hours after dosing (all, P < .05). During solriamfetol treatment, there were significant improvements in BC-CCI (P = .002; d = 0.45), PGI-S (P = .034; d = 0.29), and ESS (P = .004; d = 0.40) compared with placebo. The most common treatment-emergent adverse events were nausea (7%) and anxiety (3%). INTERPRETATION: SHARP showed that solriamfetol can improve objective and subjective measures of cognitive function in patients with cognitive impairment associated with OSA and EDS. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT04789174; URL: www. CLINICALTRIALS: gov and EudraCT; No.: 2020-004243-92; URL: https://eudract.ema.europa.eu.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CognitionSleep Apnea, ObstructiveDisorders of Excessive SomnolenceCognitive DysfunctionCarbamatesHumansMaleDouble-Blind MethodFemaleCross-Over StudiesMiddle AgedAdultTreatment OutcomeAgedPhenylalanine

Stichwörter der Autor:innen

DSSTOSAcognitive impairmentexcessive daytime sleepinesssolriamfetol

Substanzen

solriamfetolCarbamatesPhenylalanine

Autor:innen und Institutionen

  • Department of Translational Medicine and Physiology & Sleep and Performance Research Center, Washington State University, Spokane, WA.
  • Axsome Therapeutics, New York, NY. Electronic address: eleary@axsome.com.
  • Henry Ford Hospital Sleep Disorders and Research Center, Detroit, MI.
  • SleepMed, Inc, Columbia, SC; University of South Carolina School of Medicine, Columbia, SC.
  • CognitionMetrics, LLC, Stamford, CT; Albert Einstein College of Medicine, Bronx, NY.
  • NeuroTrials Research Inc, Atlanta, GA.

Förderung

  • Jazz Pharmaceuticals plc

Zitieren

APA

Van Dongen, H. P. A., Leary, E. B., Drake, C., Bogan, R., Jaeger, J., Rosenberg, R., Streicher, C., & Tabuteau, H. (2025). Results of the Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-Controlled Study (SHARP). CHEST. https://doi.org/10.1016/j.chest.2024.10.050

Vancouver

Van Dongen HPA, Leary EB, Drake C, Bogan R, Jaeger J, Rosenberg R, et al. Results of the Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-Controlled Study (SHARP). CHEST. 2025. doi:10.1016/j.chest.2024.10.050

BibTeX
@article{VanDongen2025,
  author = {Van Dongen, Hans P A and Leary, Eileen B and Drake, Christopher and Bogan, Richard and Jaeger, Judith and Rosenberg, Russell and Streicher, Caroline and Tabuteau, Herriot},
  title = {Results of the Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-Controlled Study (SHARP)},
  journal = {CHEST},
  year = {2025},
  doi = {10.1016/j.chest.2024.10.050}
}
Kostenlos starten →